Brief: ANI Pharmaceuticals Q4 Adjusted EPS USD 1 Vs. IBES Estimate USD 0.85
29/02/2024 11:50
Feb 29 (Reuters) - ANI Pharmaceuticals Q4 revenue USD 131.654 million vs. IBES estimate USD 122.2 million. * Q4 net income USD 700 thousand * Q4 operating expenses USD 124.9 million * outlook FY adjusted EPS USD 4.26-4.67 * outlook FY adjusted EBITDA USD 135-145 million
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary